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	 Versatile	2‐(alkylthio)pyrimidine‐type	and	2‐(phenacylamino)thiophene	building	blocks	(4a‐
d)	 and	16	were	 obtained	based	on	 an	 ortho	 functionalized	 thiophene	derivative	1.	 A	 novel
series	 of	 thieno[2,3‐d]pyrimidin‐4‐one	 derivatives	 with	 annelated	 bridgehead	 nitrogen
heterocycles	was	synthesized	starting	from	precursors	4	and	16	through	convenient	methods.
Cyclocondensation	of	2‐(phenacylthio)pyrimidinone	derivative	(4b)	with	sulfuric	acid	 led	 to
the	tricyclic	thiazole	derivative	5.	Initial	hydrazinolysis	of	3‐(carbethoxymethyl)pyrimidinone
derivative	 (4d)	 followed	 by	 nitrous	 acid	 deamination	 of	 the	 formed	N‐aminolactam	 (7)	 to
obtain	 a	N‐protodeamino	 analogue	8a,	 which	 on	 further	 treatment	with	 formaldehyde	 and
piperidine	 yielded	 the	 respective	 Mannich‐type	 base	 8b.	 On	 the	 other	 hand,	 initial
hydrazinolysis	 of	 3‐unsubstituted	 pyrimidinone	 derivative	 4a	 and	 subsequent	 acetylation
gave	the	condensed	3‐methyltriazole	derivative	12,	whereas	the	condensed	pyrrole	derivative
19	was	obtained	by	heterocyclization	of	2‐phenacylamine	derivative	16	with	malononitrile.
All	newly‐obtained	 thienopyrimidinones	with	annelated	bridgehead	nitrogen	were	screened
for	their	antimicrobial	activity	against	strains	of	a	representative	panel	of	Gram‐positive	and
Gram‐negative	bacteria	as	well	as	fungi	together	with	reference	drugs.	The	compounds	under
investigation	 displayed	 generally	 good	 in	 vitro	 antibacterial	 and	 antifungal	 activities,	 with
compound	 8b	 that	 has	 a	 N‐piperidinylmethyl	 moiety	 showing	 essentially	 the	 highest
inhibition	 in	 both	 assays.	 Despite	 promising	 antimicrobial	 activity	 of	 N‐1‐substituted
imidazole	 derivative	 8b,	 the	 corresponding	N‐1‐unsubstituted	 analogue	 8a	 displayed	 poor
activity.	The	heteroannelation	of	a	N‐(piperidinylmethyl)imidazole	or	3‐methyltriazole	moiety
to	 the	 thienopyrimidinone	 scaffold	 could	 be	 considered	 as	 a	 potential	 strategy	 for	 the
development	of	new	therapeutic	antimicrobial	agents.	
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1.	Introduction	
	
There	 has	 been	 an	 increasing	 demand	 for	 new	
antimicrobial	 agents,	 as	 the	 fast	 development	 of	 microbial	
resistance	to	conventional	drugs	poses	major	difficulties	in	the	
treatment	 of	 microbial	 infections,	 especially	 for	 people	 with	
impaired	immune	systems	such	as	patients	affected	with	AIDS	
and	cancer,	and	transplant	patients	[1].	In	particular,	antibiotic	
resistance	 among	 Gram‐positive	 bacteria	 (Staphylococci,	
Enterococci,	and	Streptococci)	is	becoming	increasingly	serious	
[2].	 It	 is	 known	 that	 the	 biochemical	 similarity	 of	 the	 human	
cell	and	fungi	provides	a	significant	obstacle	to	the	discovery	of	
therapeutic	agents	with	selective	activity,	but	the	emergence	of	
resistance	 is	 the	 main	 problem	 encountered	 in	 the	
development	 of	 safe	 and	 effective	 antifungals	 [3].	 In	 order	 to	
overcome	 these	 emerging	 resistance	 problems,	 there	 is	 an	
urgent	 need	 to	 discover	 new	 antimicrobial	 agents	 with	 novel	
modes	of	action.	
In	the	course	of	reviewing	various	structures	which	may	be	
of	use	 in	 the	design	of	novel	antimicrobial	agents,	azoles	have	
attracted	much	of	our	attention	because	of	their	synthetic	and	
biological	 importance.	 Among	 azoles,	 imidazole	 and	 triazole	
analogues	 are	 present	 in	 many	 effective	 antifungal	 drugs	
widely	 used	 for	 the	 treatment	 of	 topical	 or	 inner	mycoses,	 in	
particular	 AIDS‐related	 mycotic	 pathologies	 [4].	 The	 main	
effect	 of	 antifungal	 azoles	 is	 to	 block	 fungal	 ergosterol	
biosynthesis	by	preventing	 the	access	of	 the	natural	 substrate	
lanosterol	to	the	active	site	of	the	cytochrome	P‐450‐dependent	
enzyme	14α‐lanosterol	demethylase	[4,5].	Over	the	past	couple	
of	 decades,	 a	 number	 of	 antifungal	 imidazole	 agents	 were	
discovered	 and	 introduced	 in	 clinical	 practice	 such	 as	
clotrimazole,	 bifonazole	 and	miconazole,	 whereas	 fluconazole	
was	identified	as	one	of	the	most	important	antifungal	drugs	in	
the	triazole	family	[6].	Moreover,	pyrrole	and	thiazole	subunits	
are	 useful	 structural	 components	 in	 medicinal	 chemistry	 and	
have	 also	 found	 broad	 applications	 in	 antimicrobial	 drug	
developments.	 Pyrrolomycin	 B,	 used	 as	 an	 antibiotic,	
represents	 an	 example	 of	 a	 bioactive	 pyrrole	 [7].	 Such	
medicines	 as	 sulfathiazole,	 phthalylsulfathiazole	 and	 related	
compounds	are	commonly	used	in	medical	practice	as	well	[8].	
Besides,	 the	 antimicrobial	 profile	 of	 condensed	 thiophenes,	
particularly,	 their	 thieno[2,3‐d]pyrimidin‐4‐one	 analogues	 is	
also	well	categorized	in	the	literature	[9‐11].	
Based	 on	 these	 observations	 and	 as	 part	 of	 our	 ongoing	
studies	 in	 the	 development	 of	 new	 chemotherapeutic	 agents	
[12,13],	we	 embarked	 upon	 the	 synthesis	 of	 a	 series	 of	 novel	
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condensed	 tricyclic	 derivatives	 containing	 a	 thieno[2,3‐
d]pyrimidin‐4‐one	 core	 fused	 through	 N‐3	 with	 different	
heterocyclic	fragments	with	the	objective	to	develop	new	leads	
and	to	improve	their	efficacy.	
	
2.	Experimental	
2.1.	Instrumentation	
	
Melting	 points	 are	 uncorrected.	 IR	 spectra	were	 recorded	
(KBr)	 on	 a	 Pye	 Unicam	 SP‐1000	 spectrophotometer.	 NMR	
spectra	 were	 obtained	 on	 a	 Varian	 Gemini	 300	 MHz	
spectrometer	 in	 DMSO‐d6	 as	 solvent	 and	 Tetramethylsilane	
(TMS)	as	internal	reference.	Chemical	shifts	are	expressed	in	δ	
ppm.	EI	mass	spectra	were	recorded	on	a	Shimadzu	GC	MS‐QP	
1000	 EI	 mass	 spectrometer	 at	 70	 eV.	 Compound	 1	 was	
prepared	by	published	procedure	[14].	
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	N‐(3‐carbethoxy‐4‐phenyl‐5‐phenyl	
azothien‐2‐yl)‐N’‐benzoylthiourea	(2)	
	
To	 a	 solution	 of	 ammonium	 thiocyanate	 (0.26	 g,	 0.0034	
mol)	in	dry	acetone	(15	mL)	benzoyl	chloride	(0.28	mL,	0.0024	
mol)	 was	 added	 dropwise.	 To	 the	 resulting	 suspension,	 after	
being	 refluxed	 for	 5	min,	 a	 solution	 of	 amino	 ester	1	 (0.84	 g,	
0.0024	 mol)	 in	 dry	 acetone	 (60	 mL)	 was	 slowly	 added	
dropwise	and	with	constant	stirring.	The	reaction	mixture	was	
heated	at	reflux	for	2	h,	 filtered	while	hot,	 left	to	cool	to	room	
temperature	and	poured	onto	 iced	water.	The	precipitate	was	
collected	by	 filtration,	repeatedly	washed	with	cold	water	and	
dried.	 The	 thienylthiourea	 2	 can	 be	 processed	 without	
recrystallization.	 An	 analytically	 pure	 sample	 can	 be	 obtained	
by	recrytallization	from	ethanol	to	give	pale	yellow	crystals	of	
the	title	compound	2	(0.68	g;	55%).	M.p.:	153‐154	C.	IR	(ν/cm‐
1):	3312‐3240	(2NH),	3041	(arom	CH),	1677,	1672	(2CO),	1566	
(N=N).	1H	NMR	(δ	ppm):	1.35	(t,	3H,	J	=	7.2	Hz,	ester	Me),	4.46	
(q,	2H,	J	=	7.2	Hz,	ester	CH2),	7.24‐8.09	(m,	15H,	3PhH),	9.58	(s,	
1H,	 NHCS,	 D2O‐exchangeable),	 11.20	 (s,	 br,	 1H,	 NHCO,	 D2O‐
exchangeable).	MS	 (m/z	 (%)):	 514	 (M+,	15%).	Anal.	 Calcd.	 for	
C27H22N4O3S2	 (514.619):	 C,	 63.02;	 H,	 4.31;	 N,	 10.89;	 S,	 12.46.	
Found:	C,	62.79;	H,	4.20;	N,	10.71;	S,	12.21%.	
	
2.2.2.	Synthesis	of	5‐phenyl‐6‐phenylazo‐2‐thioxo‐2,3‐
dihydrothieno[2,3‐d]pyrimidin‐4(1H)‐one	(3)	
	
To	a	solution	of	potassium	hydroxide	(0.56	g,	0.01	mol)	 in	
aqueous	ethanol	(50%,	25	mL)	was	added	the	thienylthiourea	2	
(2.57	 g,	 0.005	mol).	 The	 reaction	 content	was	 refluxed	 under	
stirring	for	2	h.	After	cooling,	the	reaction	mixture	was	poured	
onto	water,	 carefully	 acidified	with	 hydrochloric	 acid	 and	 left	
under	 stirring	 at	 room	 temperature	 for	 30	 min.	 The	
precipitated	crystals	were	collected	by	 filtration,	washed	with	
cold	 water	 and	 air‐dried	 to	 give	 by	 recrystallization	 from	
ethanol/dioxane	 the	 thienopyrimidinone	 derivative	 3	 as	 a	
yellow	solid	(0.71	g;	39%).	M.p.:	191‐192	C.	IR	(ν/cm‐1):	3200,	
3100	 (2NH),	 3038	 (arom	 CH),	 1670	 (CO),	 1552	 (N=N),	 1194	
(CS).	1H	NMR	(δ	ppm):	7.16‐7.51	(m,	10H,	2PhH),	12.67	(s,	1H,	
CONH,	 D2O‐exchangeable),	 13.02	 (s,	 1H,	 NH,	 D2O‐
exchangeable).	 13C	 NMR	 (δ	 ppm):	 116.9	 (C‐4a),	 127.0,	 127.5,	
127.9,	 128.3,	 128.6,	 129.4,	 132.3,	 135.2,	 142.1,	 152.5,	 153.0,	
159.7	 (CO),	 173.9	 (CS).	 MS	 (m/z	 (%)):	 364	 (M+,	 21%).	 Anal.	
Calcd.	for	C18H12N4OS2	(364.444):	C,	59.32;	H,	3.32;	N,	15.37;	S,	
17.60.	Found:	C,	59.11;	H,	3.18;	N,	15.24;	S,	17.38%.	
	
2.2.3.	General	procedure	for	the	synthesis	of	2‐substituted‐5‐
phenyl‐6‐(phenylazo)thieno[2,3‐d]pyrimidin‐4(3H)‐ones	
4a,b		
	
A	 solution	 of	 compound	 3	 (1.82	 g,	 0.005	 mol)	 in	
dimethylformamide	 (25	 mL)	 was	 stirred	 with	 anhydrous	
potassium	 carbonate	 (1.04	 g,	 0.0075	 mol)	 and	 then	 either	
methyl	 iodide	 or	 phenacyl	 bromide	 (0.005	 mol)	 was	 added	
sequentially,	while	maintaining	the	temperature	of	the	reaction	
mixture	 at	 0‐5	 oC.	 Stirring	 was	 continued	 for	 3	 h	 at	 this	
temperature	 and	 continued	 for	 additional	 2	 h	 at	 room	
temperature.	After	treatment	with	water,	the	solid	precipitates	
were	 collected	 by	 filtration,	 dried	 and	 recrystallized	 from	 the	
proper	solvents	to	obtain	the	title	compounds	4a	(0.76	g;	40%)	
and	4b	(0.75	g;	31%),	respectively.	
	
2.2.3.1.	2‐Methylthio‐5‐phenyl‐6‐(phenylazo)thieno[2,3‐
d]pyrimidin‐4(3H)‐one	(4a)	
	
This	 compound	 was	 obtained	 as	 a	 canary	 yellow	 solid	
(ethanol).	 M.p.:	 170‐172	 C.	 IR	 (ν/cm‐1):	 3170	 (NH),	 3047	
(arom	CH),	 1662	 (lactam	CO),	 1575	 (N=N).	 1H	NMR	 (δ	 ppm):	
2.67	(s,	3H,	SMe),	7.12‐7.48	(m,	10H,	2PhH),	12.46	(s,	1H,	NH,	
D2O‐exchangeable).	13C	NMR	(δ	ppm):	13.3	(SMe),	117.2	(C‐4a),	
127.1,	 127.5,	 127.8,	 128.2,	 128.8,	 129.4,	 132.5,	 135.2,	 142.5,	
152.6,	 158.0,	 161.6	 (CO),	 163.7	 (C‐2).	 Anal.	 Calcd.	 for	
C19H14N4OS2	 (378.471):	 C,	 60.30;	 H,	 3.73;	 N,	 14.80;	 S,	 16.94.	
Found:	C,	60.13;	H,	3.57;	N,	14.58;	S,	16.74%.	
	
2.2.3.2.	2‐Phenacylthio‐5‐phenyl‐6‐(phenylazo)thieno[2,3‐
d]pyrimidin‐4(3H)‐one	(4b)	
	
This	 compound	 was	 obtained	 as	 a	 brown	 solid	
(dimethylformamide/water).	 M.p.:	 211‐212	 C.	 IR	 (ν/cm‐1):	
3186	(NH),	3054	(arom	CH),	1695,	1661	(2CO),	1570	(N=N).	1H	
NMR	 (δ	 ppm):	 5.06	 (s,	 2H,	 SCH2),	 7.22‐7.79	 (m,	 15H,	 3PhH),	
12.60	 (s,	 1H,	 NH,	 D2O‐exchangeable).	 Anal.	 Calcd.	 for	
C26H18N4O2S2	 (482.577):	 C,	 64.71;	 H,	 3.76;	 N,	 11.61;	 S,	 13.29.	
Found:	C,	64.47;	H,	3.63;	N,	11.41;	S,	13.08%.	
	
2.2.3.3.	Synthesis	of	3‐methyl‐2‐methylthio‐5‐phenyl‐6‐
(phenylazo)thieno[2,3‐d]pyrimidin‐4(3H)‐one	(4c)	
	
To	 a	 mixture	 of	 compound	 3	 (1.09	 g,	 0.003	 mol)	 and	
anhydrous	 potassium	 carbonate	 (0.88	 g,	 0.0064	 mol)	 in	
dimethylformamide	 (15	 mL),	 methyl	 iodide	 (0.37	 mL,	 0.006	
mol)	was	added	dropwise.	The	reaction	mixture	was	stirred	for	
4	h	 at	 room	 temperature.	Water	was	 added	 to	 the	mixture	 to	
form	 precipitate,	 which	 was	 collected	 by	 filtration,	 dried	 and	
purified	by	recrystallization	from	aqueous	dimethylformamide	
to	 give	 light	 brown	 crystals	 of	 the	 title	 compound	4c	 (0.61	 g;	
52%).	 M.p.:	 203‐204	 C.	 IR	 (ν/cm‐1):	 3058	 (arom	 CH),	 1669	
(CO),	1581	(N=N).	1H	NMR	(δ	ppm):	2.56	(s,	3H,	SMe),	3.61	(s,	
3H,	 NMe),	 7.14‐7.50	 (m,	 10H,	 2PhH).	 13C	 NMR	 (δ	 ppm):	 14.8	
(SMe),	 30.2	 (NMe),	 117.9,	 127.1,	 127.4,	 127.8,	 128.2,	 128.9,	
129.5,	132.6,	135.1,	142.3,	152.6,	156.7,	159.4	(C‐2),	160.5	(CO).	
Anal.	 Calcd.	 for	 C20H16N4OS2	 (392.497):	 C,	 61.20;	 H,	 4.11;	 N,	
14.27;	S,	16.34.	Found:	C,	60.95;	H,	3.96;	N,	14.10;	S,	16.12%.	
	
2.2.4.	Synthesis	of	ethyl	2‐(2‐methylthio‐4‐oxo‐5‐phenyl‐6‐
(phenylazo)thieno[2,3‐d]pyrimidin‐3(4H)‐yl)acetate	(4d)	
	
To	 a	 solution	 of	 compound	 4a	 (1.14	 g,	 0.003	 mol)	 in	
dimethylformamide	 (20	mL),	 anhydrous	 potassium	 carbonate	
(0.83	g,	0.006	mol)	was	added	and	 the	mixture	was	stirred	at	
room	temperature	for	15	min,	followed	by	the	addition	of	ethyl	
chloroacetate	 (0.40	 g,	 0.0033	mol)	 in	 dimethylformamide	 (10	
mL).	 Stirring	 was	 continued	 at	 room	 temperature	 overnight,	
according	 to	 thin	 layer	 chromatographic	 (TLC)	 analysis.	 And	
then	 ice/water	mixture	was	 added	 to	 the	 reaction	mixture	 to	
form	precipitate,	which	was	collected	by	filtration,	washed	with	
water,	dried	and	purified	by	recrystallization	from	1,4‐dioxane	
to	give	white	crystals	of	 the	 title	compound	4d	(0.68	g;	49%).	
M.p.:	159‐160	C.	IR	(ν/cm‐1):	3063	(arom	CH),	1730	(ester	CO),	
1677	 (pyrimidine	 CO),	 1567	 (N=N),	 1211	 (C‐O‐C).	 1H	NMR	 (δ	
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ppm):	1.32	(t,	3H,	J	=	7.4	Hz,	ester	Me),	2.63	(s,	3H,	SMe),	4.10	
(q,	 2H,	 J	 =	7.4	Hz,	 ester	CH2),	 4.70	 (s,	 2H,	NCH2CO),	 7.17‐7.49	
(m,	 10H,	 2PhH).	 Anal.	 Calcd.	 for	 C23H20N4O3S2	 (464.560):	 C,	
59.46;	H,	 4.34;	N,	 12.06;	 S,	 13.80.	 Found:	 C,	 59.26;	H,	 4.25;	N,	
11.87;	S,	13.62%.	
	
2.2.5.	Synthesis	of	3,6‐diphenyl‐7‐phenylazo‐5H‐thiazolo	
[3,2‐a]thieno[2,3‐d]pyrimidin‐5‐one	(5)	
	
To	 1.45	 g	 (0.003	 mol)	 of	 4b	 was	 added	 concentrated	
sulfuric	 acid	 (5	 mL,	 0.09	 mol)	 dropwise.	 The	 mixture	 was	
stirred	at	room	temperature	for	72	h.	The	reaction	mixture	was	
poured	over	iced	water	with	stirring.	The	resulting	precipitate	
of	 solid	 product	 was	 collected	 by	 filtration,	 washed	 with	
sodium	 carbonate	 solution,	 followed	 by	 water	 and	
recrystallized	 from	 ethanol/dioxane	 mixture	 to	 obtain	 the	
corresponding	 3‐phenylthiazole	 derivative	5	 as	 a	 dark	 brown	
solid	(0.75	g;	54%).	M.p.:	219‐220	C.	IR	(ν/cm‐1):	3060	(arom	
CH),	 1704	 (CO),	 1556	 (N=N).	 1H	 NMR	 (δ	 ppm):	 6.97	 (s,	 1H,	
thiazole	 H‐2),	 7.20‐7.63	 (m,	 15H,	 3PhH).	 13C	 NMR	 (δ	 ppm):	
111.3	 (C‐2),	 117.5,	 127.0,	 127.3,	 127.7,	 127.9,	 128.1,	 128.4,	
128.7,	 129.2,	 129.6,	 132.4,	 133.5,	 135.3,	 142.6,	 146.2,	 152.5,	
156.8,	158.1,	161.8	 (CO).	MS	 (m/z	 (%)):	464	 (M+,	24%).	Anal.	
Calcd.	for	C26H16N4OS2	(464.561):	C,	67.22;	H,	3.47;	N,	12.06;	S,	
13.80.	Found:	C,	67.05;	H,	3.32;	N,	11.85;	S,	13.61%.	
	
2.2.6.	Synthesis	of	1‐amino‐6‐phenyl‐7‐(phenylazo)	
imidazo[1,2‐a]thieno[2,3‐d]pyrimidine‐2,5(1H,3H)‐dione	(7)		
	
Compound	 4d	 (0.93	 g,	 0.002	 mol)	 was	 mixed	 with	
hydrazine	hydrate	(8	mL,	0.16	mol)	in	absolute	ethanol	(20	mL)	
and	 the	 mixture	 was	 gently	 refluxed.	 The	 solid	 went	 into	
solution	within	 10	min.	 After	 30	min,	when	 the	 solid	 product	
started	 separating,	 heating	was	discontinued	and	 the	 reaction	
mixture	 was	 allowed	 to	 cool	 to	 room	 temperature.	 The	 solid	
which	 separated	 was	 filtered	 off,	 washed	 with	 water	 and	
ethanol,	 and	 dried.	 Recrystallization	 from	dimethylformamide	
gave	yellowish	white	crystals	of	the	N‐amino	compound	7	(0.60	
g;	75%).	M.p.:	233‐236	C.	IR	(ν/cm‐1):	3325,	3230	(NH2),	3052	
(arom	CH),	 1721,	 1680	 (2CO),	 1572	 (N=N).	 1H	NMR	 (δ	ppm):	
4.80	 (s,	 2H,	 NH2,	 D2O‐exchangeable),	 4.92	 (s,	 2H,	 imidazole	
CH2),	 7.16‐7.48	 (m,	 10H,	 2PhH).	 Anal.	 Calcd.	 for	 C20H14N6O2S	
(402.429):	C,	59.69;	H,	3.51;	N,	20.88;	S,	7.97.	Found:	C,	59.46;	
H,	3.32;	N,	20.67;	S,	7.81%.	
	
2.2.7.	Synthesis	of	6‐phenyl‐7‐(phenylazo)imidazo[1,2‐a]	
thieno[2,3‐d]pyrimidine‐2,5(1H,3H)‐dione	(8a)		
	
Compound	 7	 (1.21	 g,	 0.003	 mol)	 was	 dissolved	 in	 acetic	
acid	(20	mL),	a	small	amount	of	insoluble	material	was	filtered	
off,	then	the	liquid	was	cooled	in	ice	bath	at	0‐5	oC.	The	solution	
was	 stirred	 at	 this	 temperature	 and	 treated	 gradually	 with	 a	
cold	saturated	solution	of	sodium	nitrite	[1	g	of	sodium	nitrite	
(0.015	mol)	in	water	(10	mL)]	over	a	period	of	15	min.	Stirring	
was	 continued	 for	 further	 30	 min,	 then	 the	 reaction	 mixture	
was	 left	 to	 stand	 at	 room	 temperature	 for	 3	 h.	 The	 resulting	
solid	 was	 filtered	 off,	 washed	 with	 water	 and	 dried.	
Recrystallization	from	ethanol	gave	the	title	compound	8a	as	a	
colourless	 solid	 (0.80	 g;	 69%).	M.p.:	 254‐255	 C.	 IR	 (ν/cm‐1):	
3315	(NH),	3056	(arom	CH),	1710,	1680	(2CO),	1561	(N=N).	1H	
NMR	(δ	ppm):	4.89	 (s,	2H,	 imidazole	CH2),	7.19‐7.48	 (m,	10H,	
2PhH),	11.83	(s,	1H,	NH,	D2O‐exchangeable).	MS	(m/z	(%)):	387	
(M+,	14%).	Anal.	Calcd.	 for	C20H13N5O2S	(387.415):	C,	62.00;	H,	
3.38;	 N,	 18.08;	 S,	 8.28.	 Found:	 C,	 61.76;	 H,	 3.21;	 N,	 17.90;	 S,	
8.14%.	
	
2.2.8.	Synthesis	of	6‐phenyl‐7‐phenylazo‐1‐(piperidin‐1‐
ylmethyl)imidazo[1,2‐a]thieno[2,3‐d]pyrimidine‐2,5	
(1H,3H)‐dione	(8b)	
	
To	a	stirred	solution	of	compound	8a	(1.94	g,	0.005	mol)	in	
methanol	 (10	 mL),	 formaldehyde	 (37%	 aqueous	 solution,	 1	
mL)	 was	 added.	 A	 second	 methanolic	 solution	 (2.5	 mL)	 of	
piperidine	 (0.50	mL,	 0.005	mol)	was	 added	 portionwise	 over	
the	 first	 solution.	 The	 mixture	 was	 stirred	 for	 3	 h	 at	 room	
temperature	 and	 left	 overnight	 in	 a	 refrigerator.	 The	
precipitate	 formed	 was	 filtered	 off,	 washed	 with	 petroleum	
ether,	dried	and	recrystallized	 from	ethanol/water	 to	give	 the	
Mannich	 base	 8b	 as	 a	 dark	 brown	 solid	 (0.73	 g;	 30%).	 M.p.:	
269‐271	 C.	 IR	 (ν/cm‐1):	 3062	 (arom	 CH),	 1724,	 1682	 (2CO),	
1565	(N=N).	1H	NMR	(δ	ppm):	1.61	(m,	6H,	3CH2),	3.15	(t,	4H,	
N[CH2]2),	 4.87	 (s,	 2H,	 imidazole	 CH2),	 4.98	 (s,	 2H,	 CH2),	 7.22‐
7.50	(m,	10H,	2PhH).	MS(m/z	(%)):	484	(M+,	29%).	Anal.	Calcd.	
for	C26H24N6O2S	 (484.573):	C,	64.44;	H,	4.99;	N,	17.34;	S,	6.62.	
Found:	C,	64.23;	H,	4.81;	N,	17.14;	S,	6.51%.	
	
2.2.9.	Synthesis	of	2‐hydrazinyl‐5‐phenyl‐6‐(phenylazo)	
thieno[2,3‐d]pyrimidin‐4(3H)‐one	(9)	
	
A	 mixture	 of	 compound	 4a	 (1.14	 g,	 0.003	 mol)	 and	
hydrazine	hydrate	(1.5	mL,	0.03	mol)	was	refluxed	in	15	mL	of	
absolute	ethanol	for	4	h.	The	solid	product,	which	precipitated	
during	 refluxing	 was	 collected	 by	 filtration	 and	 dried.	
Recrystallization	 from	 1,4‐dioxane	 gave	 the	 hydrazino	
derivative	9	 as	 pale	 yellow	 crystals	 (0.71	 g;	 65%).	M.p.:	 240‐
241	 C.	 IR	 (ν/cm‐1):	 3380‐3237	 (2NH,	NH2),	 3065	 (arom	CH),	
1660	(CO),	1577	(N=N).	1H	NMR	(δ	ppm):	3.75	(s,	2H,	NH2,	D2O‐
exchangeable),	7.14‐7.44	(m,	10H,	2PhH),	9.23	(s,	1H,	NH,	D2O‐
exchangeable),	 12.51	 (s,	 1H,	 CONH,	 D2O‐exchangeable).	 13C	
NMR	 (δ	ppm):	 115.8,	 127.2,	 127.6,	 127.9,	 128.4,	 128.8,	 129.5,	
132.5,	135.1,	142.5,	152.4,	156.5,	157.0,	160.9	(CO).	Anal.	Calcd.	
for	 C18H14N6OS	 (362.408):	 C,	 59.65;	H,	 3.89;	N,	 23.19;	 S,	 8.85.	
Found:	C,	59.43;	H,	3.75;	N,	23.02;	S,	8.65%.	
	
2.2.10.	Synthesis	of	3‐acetyl‐2‐methylthio‐5‐phenyl‐6‐
(phenylazo)thieno[2,3‐d]pyrimidin‐4(3H)‐one	(13)	
	
A	 solution	 of	 compound	4a	 (1.89	 g,	 0.005	mol)	 in	 7.5	ml	
(0.079	mol)	of	acetic	anhydride	was	heated	under	reflux	for	1	h.	
The	 solution	 was	 then	 poured	 onto	 75	 mL	 ice/water	 and	
stirred	for	several	hours	until	crystallization	was	complete.	The	
material	which	separated	out	was	isolated	by	filtration,	washed	
with	water	and	dried.	It	was	recrystallized	from	ethanol	to	give	
the	 corresponding	 N‐acetyl	 derivative	 13	 as	 reddish	 brown	
crystals	 (0.84	 g;	 40%).	 M.p.:	 227‐229	 C.	 IR	 (ν/cm‐1):	 3066	
(arom	CH),	 1690,	 1681	 (2CO),	 1550	 (N=N).	 1H	NMR	 (δ	ppm):	
2.47,	2.65	(2s,	6H,	2Me),	7.20‐7.51	(m,	10H,	2PhH).	13C	NMR	(δ	
ppm):	15.1	(SMe),	24.9	(acetyl	Me),	117.3,	127.0,	127.3,	127.8,	
128.1,	 128.7,	 129.1,	 132.7,	 135.4,	 142.5,	 152.6,	 157.3,	 158.4,	
159.8	 (pyrimidine	 CO),	 167.2	 (acetyl	 CO).	 Anal.	 Calcd.	 for	
C21H16N4O2S2	 (420.507):	 C,	 59.98;	 H,	 3.84;	 N,	 13.32;	 S,	 15.25.	
Found:	C,	59.73;	H,	3.68;	N,	13.11;	S,	15.06%.	
	
2.2.11.	Synthesis	of	3‐methyl‐6‐phenyl‐7‐(phenylazo)	
thieno[2,3‐d][1,2,4]triazolo[4,3‐a]pyrimidin‐5(1H)‐one	(12)	
	
2.2.11.1.	Method	A	
	
This	compound	was	synthesized	from	hydrazino	compound	
9	in	a	manner	similar	to	that	described	before	for	the	synthesis	
of	compound	13	(reaction	time:	4	h).	It	was	recrystallized	from	
acetic	acid	to	give	the	respective	3‐methyltriazole	derivative	12	
as	 a	 brown	 solid	 (0.68	 g;	 35%).	 M.p.:	 >	 300	 C.	 IR	 (ν/cm‐1):	
3140	(NH),	3059	(arom	CH),	1698	(CO),	1566	(N=N).	1H	NMR	
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(δ	ppm):	2.36	(s,	3H,	Me),	7.18‐7.51	(m,	10H,	2PhH),	10.57	(s,	
1H,	NH,	D2O‐exchangeable).	13C	NMR	(δ	ppm):	19.1	(Me),	117.5,	
127.3,	 127.6,	 128.0,	 128.4,	 128.9,	 129.2,	 132.6,	 135.4,	 142.3,	
148.5,	151.8,	152.4,	157.0,	162.7	(CO).	MS	(m/z	(%)):	386	(M+,	
17%).	Anal.	Calcd.	 for	C20H14N6OS	(386.430):	C,	62.16;	H,	3.65;	
N,	21.75;	S,	8.30.	Found:	C,	61.98;	H,	3.50;	N,	21.52;	S,	8.11%.	
	
2.2.11.2.	Method	B	
	
A	mixture	of	 compound	13	 (0.84	g,	0.002	mol),	hydrazine	
hydrate	 (1	 mL,	 0.02	 mol)	 in	 absolute	 ethanol	 (8	 mL)	 was	
refluxed	 for	 8	 h.	 After	 cooling	 overnight	 and	 dilution	 with	
water,	 the	 separated	 solid	product	was	 collected	by	 filtration,	
dried	and	purified	by	recrystallization	from	acetic	acid	to	give	a	
solid	product,	in	55%	yield,	identical	in	every	respect	(Melting	
point,	mixed	melting	point	and	IR	data)	to	that	obtained	above	
from	method	A.	
	
2.2.11.3.	Method	C		
	
A	 solution	 of	 hydrazino	 compound	 9	 (0.72	 g,	 0.002	 mol)	
and	acetylacetone	(0.002	mol)	in	ethanol	(20	mL)	was	refluxed	
for	 4	 h.	 Most	 of	 the	 solvent	 was	 removed	 under	 reduced	
pressure	and	the	residue	was	purified	by	recrystallization	from	
acetic	 acid	 to	 give	 a	 solid	 product	 in	 49%	 yield.	 Again,	 this	
product	was	identified	as	12.	
	
2.2.12.	Synthesis	of	ethyl	2‐(2‐oxo‐2‐phenylethylamino)‐4‐
phenyl‐5‐(phenylazo)thiophene‐3‐carboxylate	(16)		
	
A	mixture	of	phenacyl	bromide	(1	g,	0.005	mol)	in	15	mL	of	
dimethylformamide	and	triethylamine	(two	drops)	was	stirred	
until	 homogeneity.	 Amino	 ester	 1	 (1.76	 g,	 0.005	 mol)	 was	
added	 to	 the	 solution	 and	 then	 the	 reaction	 content	 was	
refluxed	 under	 stirring	 for	 4	 h.	 Upon	 cooling,	 a	 solid	 was	
obtained	which	was	collected	by	filtration,	washed	with	water,	
dried	 and	 purified	 by	 recrystallization	 from	 ethanol	 to	 obtain	
the	 title	 compound	 16	 as	 white	 crystals	 (0.87	 g;	 37%).	 M.p.:	
142‐143	 C.	 IR	 (ν/cm‐1):	 3163	 (NH),	 3045	 (arom	 CH),	 1679,	
1671	(2CO),	1574	(N=N).	1H	NMR	(δ	ppm):	1.31	(t,	3H,	J	=	7.2	
Hz,	 ester	Me),	 4.45	 (q,	 2H,	 J	 =	 7.2	Hz,	 ester	 CH2),	 4.91	 (d,	 2H,	
CH2),	 7.28‐7.84	 (m,	 15H,	 3PhH),	 8.25	 (s,	 br,	 1H,	 NH,	 D2O‐
exchangeable).	MS	 (m/z	 (%)):	 469	 (M+,	19%).	Anal.	 Calcd.	 for	
C27H23N3O3S	 (469.555):	 C,	 69.06;	 H,	 4.94;	 N,	 8.95;	 S,	 6.83.	
Found:	C,	68.82;	H,	4.77;	N,	8.76;	S,	6.67%.	
	
2.2.13.	Synthesis	of	ethyl	2‐(2‐amino‐3‐cyano‐4‐phenyl‐1H‐
pyrrol‐1‐yl)‐4‐phenyl‐5‐(phenylazo)thiophene‐3‐carboxylate	
(18)		
	
Compound	 16	 (5.87	 g,	 0.0125	 mol)	 was	 mixed	 with	 an	
equivalent	 amount	 of	 malononitrile	 (0.83	 g,	 0.0125	 mol)	 in	
ethanol	 (10	 mL)	 containing	 a	 catalytic	 amount	 of	 piperidine	
(0.25	mL).	 The	 reaction	 content	was	 heated	 at	 reflux	 for	 1	 h,	
concentrated	 and	 then	 held	 at	 room	 temperature	 for	 30	min.	
After	cooling	and	dilution	with	water,	the	obtained	precipitate	
was	filtered	off,	dried	and	purified	by	recrystallization	from	an	
ethanol	 and	 dimethylformamide	 mixture	 to	 give	 orange	
crystals	of	the	enaminonitrile	derivative	18	(1.94	g;	30%).	M.p.:	
183‐184	 C.	 IR	 (ν/cm‐1):	 3412,	 3325	 (NH2),	 3070	 (arom	 CH),	
2206	 (CN),	1730	 (CO),	1590	 (N=N).	 1H	NMR	 (δ	ppm):	1.27	 (t,	
3H,	J	=	7.2	Hz,	ester	Me),	4.39	(q,	2H,	J	=	7.2	Hz,	ester	CH2),	6.31	
(s,	 br,	 2H,	 NH2,	 D2O‐exchangeable),	 6.98	 (s,	 1H,	 pyrrole	 H‐5),	
7.11‐7.52	 (m,	 15H,	 3PhH).	 Anal.	 Calcd.	 for	 C30H23N5O2S	
(517.601):	C,	69.61;	H,	4.48;	N,	13.53;	S,	6.19.	Found:	C,	69.42;	
H,	4.33;	N,	13.28;	S,	6.07%.	
	
2.2.14.	Synthesis	of	4‐oxo‐3,7‐diphenyl‐2‐phenylazo‐4,5‐
dihydropyrrolo[1,2‐a]thieno[3,2‐e]pyrimidine‐6‐
carbonitrile	(19)	
	
2.2.14.1.	Method	A		
	
Compound	 18	 (1.04	 g,	 0.002	 mol)	 was	 dissolved	 in	 a	
solution	of	sodium	ethoxide	(from	0.05	g,	0.0022	mol	of	sodium	
metal	 and	 10	 mL	 of	 absolute	 ethanol)	 and	 the	 solution	 was	
heated	 at	 reflux	 for	 2	 h.	 The	 sodium	 salt	 was	 collected	 by	
filtration,	 then	 dissolved	 in	 water	 and	 neutralized	 with	
hydrochloric	 acid.	 The	 product	 which	 separated	 was	 filtered	
off,	washed	with	ethanol,	dried	and	purified	by	recrystallization	
from	dimethylformamide	to	give	brown	crystals	of	the	pyrrole	
derivative	19	(0.62	g;	66%).	Mp.:	276‐278	C.	IR	(ν/cm‐1):	3195	
(NH),	3068	(arom	CH),	2210	(CN),	1667	(CO),	1585	(N=N).	1H	
NMR	 (δ	 ppm):	 6.87	 (s,	 1H,	 pyrrole	 H‐8),	 7.13‐7.49	 (m,	 15H,	
3PhH),	12.35	(s,	1H,	NH,	D2O‐exchangeable).	MS	(m/z	(%)):	471	
(M+,	23%).	Anal.	 Calcd.	 for	C28H17N5OS	 (471.532):	 C,	 71.32;	H,	
3.63;	 N,	 14.85;	 S,	 6.80.	 Found:	 C,	 71.09;	 H,	 3.50;	 N,	 14.63;	 S,	
6.69%.	
	
2.2.14.2.	Method	B		
	
To	 a	 solution	 of	 sodium	 ethoxide	 (from	 0.0022	 mol	 of	
sodium	 metal	 and	 10	 mL	 of	 absolute	 ethanol)	 each	 of	
compound	 16	 (0.94	 g,	 0.002	 mol)	 and	 malononitrile	 (0.13	 g,	
0.002	mol)	were	added.	The	reaction	mixture	was	processed	as	
described	above	in	method	A	(reaction	time:	5	h).	The	material	
obtained	 after	 recrystallization	 from	 dimethylformamide	
proved	to	be	19	(59%	yield).	
	
2.3.	Microbiology	
	
2.3.1.	Antimicrobial	activity	
	
The	 antimicrobial	 activity	 was	 investigated	 on	 six	 newly‐
obtained	 condensed	 thiophenes	 containing	 different	 N‐
heterocyclic	moieties.	The	antimicrobial	profile	was	evaluated	
by	 measuring	 the	 inhibitory	 effects	 and	 the	 potency	 of	 such	
compounds	against	Gram‐positive,	Gram‐negative	bacteria	and	
fungi	 using	 the	 agar	 diffusion	 technique	 [15,16].	 Screening	
results	are	summarized	in	Tables	1	and	2.	
	
2.3.2.	Organisms	and	maintenance	
	
Staphylococcus	 aureus,	 Pseudomonas	 aeruginosa,	 Candida	
albicans	and	Aspergillus	fumigatus	were	used	against	the	tested	
compounds	and	were	obtained	from	Faculty	of	Agriculture,	Ain	
Shams	University.	Chloramphenicol	and	fluconazole	were	used	
as	 reference	 drugs	 and	 were	 also	 obtained	 from	 the	
pharmaceutical	factories	in	Egypt.	
The	 bacterial	 strains	 were	 cultured	 on	 nutrient	 agar,	 C.	
albicans	was	maintained	on	Yeast‐malt	extracts	medium	(YM),	
while	A.	fumigatus	was	maintained	on	Czapeck‐Dox	medium.	
	
2.3.3.	Method	
	
2.3.3.1.	Preparation	of	bacterial	suspensions	
	
Suspension	 of	 the	 above	 mentioned	 bacterial	 strains	 was	
prepared	 by	 inoculating	 fresh	 stock	 cultures	 into	 separate	
broth	 tubes,	 each	 containing	 7	mL	 of	 nutrient	 broth	 (pepton,	
0.3%)	 beef	 extract	 (0.3%).	 The	 inoculated	 tubes	 were	
incubated	at	37±2°C	for	24	h.	
	
2.3.3.2.	Preparation	of	solutions	of	the	tested	compounds	
and	reference	drugs		
	
Solutions	 of	 the	 tested	 compounds	 and	 reference	 drugs	
were	prepared	by	dissolving	0.5	g	of	the	compound	in	dimethyl	
sulfoxide	(10	mL).	
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Table	1.	Antibacterial	activity	of	test	compounds	and	reference	druga.	
Sample	
IZDb (mm)
G	+ve G	‐ve	
S.	aureus	 Potency P.	aeruginosa	 Potency
Control		 0	 0.0 0	 0.0
Standardc	 22±0.5	 1.0 21±0.2	 1.0
5	 23±0.4	 1.05 19±0.6	 0.90
7	 12±0.1	 0.55 11±0.2	 0.53
8a	 11±0.3	 0.50 9±0.4	 0.43
8b	 20±0.7	 0.91 22±0.8	 1.05
12	 15±0.2	 0.68 16±0.7	 0.76
19	 14±0.1	 0.64 15±0.5	 0.71
a	DMSO	has	no	antibacterial	activity	at	the	concentration	used	to	dissolve	the	test	compounds.	
b	IZD:	inhibition	zone	diameter.		
c	Standard	for	bacteria:	chloramphenicol.	
	
	
Table	2.	Antifungal	activity	of	test	compounds	and	reference	druga	
Sample	
IZDb (mm)
Mould Yeast	
A.	fumigatus	 Potency C.	albicans	 Potency
Control		 0	 0.0 0	 0.0
Standardc		 13±0.2	 1.0 16±0.3	 1.0
5	 13±0.4	 1.0 17±0.1	 1.06
7	 6±0.7	 0.46 11±0.1	 0.69
8a	 4±0.01	 0.30 12±0.5	 0.75
8b	 10±0.6	 0.77 17±0.2	 1.06
12	 9±0.1	 0.69 18±0.4	 1.13
19	 6±0.04	 0.46 11±0.08	 0.69
a	DMSO	has	no	antibacterial	activity	at	the	concentration	used	to	dissolve	the	test	compounds.	
b	IZD:	inhibition	zone	diameter.		
c	Standard	for	fungi:	fluconazole.	
	
	
2.3.3.3.	Determination	of	minimum	inhibitory	concentration	
(MIC)		
	
Determination	 of	 the	 MIC	 of	 compound	 12	 against	 C.	
albicans	and	compound	8b	against	P.	aeruginosa	was	achieved	
using		a		96‐well		microbioassay		system		[17].		MIC		value		was	
given	 in	 µg/ml	 and	 was	 compared	 to	 MIC	 value	 for	 relevant	
standard	drug	in	each	case	(Table	3).		
	
Table	 3.	 MIC	 (µg/mL)	 of	 compound	 8b	 and	 chloramphenicol	 against															
P.	aeruginosa,	and	compound	12	and	fluconazole	against	C.	albicans.	
Sample		 MIC	(µg/mL)	
Compound	8b		 15.5±0.06	
Chloramphenicol		 18.0±0.03	
Compound	12	 13.5±0.03	
Fluconazole		 17.5±0.04	
	
3.	Results	and	discussion	
3.1.	Chemistry	
The	 starting	 ethyl	 2‐amino‐4‐phenyl‐5‐(phenylazo)thio‐
phene‐3‐carboxylate	 (1)	 [14]	 reacted	 with	 benzoyl	 isothio‐
cyanate,	 in	 situ	 prepared	 [18],	 in	 acetone	 to	 give	 the	
corresponding	 N'‐benzoylthiourea	 derivative	 2	 (Scheme	 1).	
Treatment	of	the	latter	product	with	an	aqueous	alcoholic	(1:1)	
solution	 of	 potassium	 hydroxide	 caused	 an	 intramolecular	
cyclization	 to	 afford	 the	 2‐thioxothienopyrimidin‐4‐one	
derivative	3.	The	regioselective	alkylation	of	3	was	achieved	by	
slow	addition	of	 equivalent	 amounts	 of	 each	of	methyl	 iodide	
and	 phenacyl	 bromide	 in	 alkaline	 medium	 leading	 to	 the	 S‐
alkylated	products	4a,b,	 respectively,	which	are	unsubstituted	
at	the	N‐3	position	as	indicated	by	spectroscopic	studies.	In	the	
1H	NMR	spectra,	the	NH	protons	were	deshielded	and	appeared	
in	 the	 downfield	 region	 (δH	 12.46‐12.60	 ppm)	 due	 to	 the	
deshielding	effects	of	the	neighbouring	carbonyl	groups.	These	
data	are	in	accordance	with	literature	assignments,	that	predict	
these	NH	protons	would	resonate	in	the	downfield	region	(δH	~	
12	 ppm)	 by	 analogy	 with	 related	 lactam	 species	 [19‐22].	
Similarly,	 the	 IR	 spectra	were	also	 informative	 in	 establishing	
the	 structure	 of	 3‐unsubstituted	 pyrimidin‐4‐ones	 4a,b.	 The	
spectra	were	well	characterized	by	the	presence	of	absorption	
bands	 belonging	 to	 stretching	 vibrations	 of	 amidic	 carbonyl	
groups	at	the	typical	low	frequencies	(ν	1661‐1662	cm‐1)	and	of	
cyclic	secondary	amides	(ν	3170‐3186	cm‐1).	Similar	stretching	
frequencies	have	been	reported	on	closely	related	heterocyclic	
amide	systems	[23‐25].	Moreover,	the	13C	NMR	spectrum	of	4a	
displayed	 distinct	 shifts	 of	 nineteen	 carbon	 atoms.	 Among	
these,	 three	 important	 shifts	 at	δC	13.3,	 161.6	 and	 163.7	 ppm	
were	 characteristic	 for	 the	 SMe,	 lactam	 CO	 and	 C‐2	 carbons,	
respectively,	 thus	 lending	 additional	 support	 to	 the	 structural	
assignments.	 The	 prevalence	 of	 the	 lactam	 (oxo)	 form	 in	
compounds	4a,b	was	 further	 verified	 on	 the	 basis	 of	 a	 direct	
comparison	 of	 the	 13C	 NMR	 spectra	 of	 the	 monomethyl	
derivative	4a	and	the	corresponding	dimethylated	analogue	4c,	
which	 was	 obtained	 from	 the	 methylation	 of	 2‐thiouracil	
derivative	3	with	 two	equivalent	amounts	of	methyl	 iodide.	 It	
can	be	seen	that	the	13C	chemical	shift	of	the	C‐4	resonance	in	
compound	4c	(δC	160.5	ppm)	is	close,	with	a	slight	upfield	shift,	
to	 the	 corresponding	 signal	 in	 parent	 compound	 4a,	 thus	
indicating	 the	 presence	 of	 a	 lactam	 CO	 in	 4c.	 Also,	 the	
appearance	of	a	methyl	carbon	signal	at	the	typical	upfield	shift	
(δC	30.2	ppm)	characteristic	for	N‐3‐methyl	resonance	position	
[26]	provided	strong	evidence	in	support	of	 lactam	formation.	
O‐Methylation	should	 lead	 to	downfield	shifts	at	both	C‐4	and	
Me	 resonance	 positions	 [26,27].	 Furthermore,	 a	 relatively	
deshielded	SMe	 signal	 (δC	 14.8	ppm)	and	a	 large	 shielded	C‐2	
signal	(δC	159.4	ppm)	were	also	observed	in	the	spectrum	of	N‐
3‐methylated	 pyrimidinone	 4c	 as	 compared	 with	 that	 of	 the	
corresponding	 N‐3‐protodemethylated	 analogue	 4a.	 Similar	
assignments	 have	 been	 reported	 on	 closely	 related	 N‐3‐
methyllactams	[26].	These	observations	led	us	to	conclude	that	
the	 most	 stable	 form	 in	 the	 solvent	 for	 the	 2‐(alkylthio)	
thienopyrimidin‐4‐ones	4	is	the	lactam	(oxo)	form	rather	than	
the	 lactim	 (enol)	 form.	 In	 a	 similar	 fashion,	 the	 structure	
assigned	to	lactams	4	is	supported	by	the	1H	NMR	spectrum	of	
4c.	The	spectrum	showed	the	disappearance	of	the	NH	proton	
and	the	appearance	of	a	diagnostic	singlet	signal	at	δH	3.61	ppm	
arising	from	the	N‐methyl	protons.		
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Reagents	 and	 conditions:	 (a)	 PhCONCS,	 Me2CO,	 reflux;	 (b)	 KOH,	 EtOH,	 reflux;	 (c)	 MeI,	 K2CO3,	 DMF,	 0‐5	 oC;	 (d)	
PhCOCH2Br,	K2CO3,	DMF,	0‐5	oC;	(e)	2MeI,	K2CO3,	DMF,	r.t.;	(f)	ClCH2CO2Et,	EtOH,	reflux;	(g)	H2SO4,	r.t.;	(h)	N2H4.H2O,	
EtOH,	reflux;	(i)	NaNO2,	AcOH,	0‐5	oC;	(j)	HCHO,	HN(CH2)5,	MeOH,	r.t. 
r.t.=	room	temperature	
	
Scheme	1
	
	
This	 shift	 is	 characteristic	 for	 a	 N‐3‐methyl	 group,	 which	
has	been	reported	by	Ram	et	al.	[28],	and	by	others	[29‐31],	to	
experience	 a	 further	 downfield	 shift	 to	 around	 δH	 ~	 3.5	 ppm	
due	to	the	additional	deshielding	effect	of	the	adjacent	carbonyl	
moiety.	 The	 remaining	 resonances	 were	 also	 observed	 at	 the	
expected	 frequencies	 (see	 Experimental	 section).	 For	 the	
isomeric	 N‐1‐methylated	 analogue,	 the	 corresponding	 shift	 of	
N‐1‐Me	moves	upfield	to	around	δH	~	3.2	ppm	[28,29],	whereas	
O‐methylation	 produces	 a	 downfield	 shift	 of	 the	 methyl	
resonance,	 which	 is	 consistently	 found	 at	 δH	 ca.	 4.0	 ppm	
[29,32].	The	prevalence	of	the	3H‐	rather	than	the	1H‐form	in	a	
number	 of	 2‐(alkylthio)uracils	 is	 well	 documented	 [20‐
22,28,33‐35].	Consequently,	it	 is	not	unreasonable	to	conclude	
that	our	studied	alkylation	reactions	take	place	with	complete	
selectivity,	 since	 the	 site	 of	 alkylation	 is	 initially	 the	 sulfur	
rather	 than	 the	 nitrogen	 and	 in	 the	 case	 of	 the	 disubstituted	
products	the	N‐3	is	the	second	position	for	alkylation.	
As	discussed	above,	N‐3‐alkylated	 lactam	4d	could	also	be	
obtained	in	a	selective	manner	by	reacting	compound	4a	with	
ethyl	 chloroacetate	 in	 dimethylformamide	 in	 the	 presence	 of	
potassium	 carbonate.	 All	 spectroscopic	 data	 fitted	 perfectly	
with	 the	 proposed	 structure	4d.	 In	 its	 IR	 spectrum,	 the	 ester	
carbonyl	 stretching	 frequency	 was	 observed	 at	 ν	 1730	 cm‐1.	
Also,	 its	 1H	NMR	 spectrum	 showed	 the	 presence	 of	 a	 pattern	
corresponding	to	an	ethyl	group	as	a	triplet	and	quartet	at	1.32	
and	4.10	ppm,	respectively.	Other	resonances	were	observed	as	
expected	 and	 are	 recorded	 in	 the	 experimental	 section.	
Cyclodehydration	 of	4b	 in	 sulfuric	 acid	 at	 room	 temperature	
occurred	 readily	 with	 the	 formation	 of	 the	 corresponding	
condensed	 thiazole	 derivative	 5,	 whose	 IR	 spectrum	 lacks	
bands	belonging	 to	both	NH	and	CO	 functions,	 supporting	 the	
formation	 of	 the	 thiazole	 ring.	 In	 the	 1H	 NMR	 spectrum	 of	
compound	5,	 the	 absence	 of	 signals	 corresponding	 to	 the	NH	
and	 CH2	 protons,	 present	 in	 the	 parent	 S‐alkylated	 derivative	
4b,	 also	 verified	 ring	 closure	 through	 cyclodehydration.	 The	
structure	 assigned	 to	 the	 reaction	 product	 was	 further	
supported	by	its	13C	NMR	spectrum	(see	Experimental	section).	
On	 reaction	 with	 hydrazine	 hydrate,	 the	 N‐3‐alkylated	
pyrimidinone	4d	gave	a	product	which	might	be	assigned	 the	
structure	 of	 a	 1,2,4‐triazinone	 6	 or	 aminoimidazolidinone	 7.	
The	 signals	 for	 the	 protons	 of	 the	 ethyl	 ester	 and	methylthio	
groups,	 present	 in	 the	 1H	 NMR	 spectrum	 of	 4d,	 were	 not	
detectable	 for	 the	 isolated	 product,	 demonstrating	 the	
disappearance	 of	 these	 groups	 on	 ring	 closure.	 Elemental	
analysis	data	could	not	discriminate	between	the	two	isomeric	
structures	 6	 and	 7	 as	 both	 structures	 had	 the	 composition	
C20H14N6O2S.	 However,	 the	 structure	 of	 the	 isolated	 product	
was	 considered	 to	 be	 the	 N‐aminolactam	 7	 rather	 than	 the	
alternative	 triazinone	 6	 as	 evidenced	 by	 spectroscopic	
investigations	 as	well	 as	 a	 chemical	 transformation.	 In	 the	 1H	
NMR	 spectrum	 of	 the	 reaction	 product,	 the	 presence	 of	 only	
one	 D2O‐exchangeable	 singlet	 signal	 provided	 confirmatory	
evidence	 for	 N‐aminolactam	 formation.	 In	 support	 of	 this	
hypothesis,	the	possibility	of	formation	of	the	triazinone	6	was	
ruled	out	chemically	on	the	basis	of	the	successful	deamination	
of	 isolated	 product,	 where	 its	 treatment	 with	 sodium	 nitrite	
and	acetic	acid	led	to	the	respective	1‐protodeamino	analogue	
8a.	 This	 observation	 is	 in	 complete	 agreement	 with	 previous	
literature	 reports	 on	 the	 well	 established	 nitrous	 acid	
deamination	of	 the	 exocyclic	 amino	 group	 in	 related	 cyclic	N‐
aminoamides	[36‐39].	Compound	8a	displayed	a	molecular	ion	
peak,	which	confirmed	its	molecular	formula.	The	constitution	
of	compound	8a	was	also	well	supported	by	 its	conversion	 to	
the	 corresponding	 Mannich‐type	 base	 8b	 on	 treatment	 with	
formaldehyde	and	piperidine	as	a	secondary	amine	(Scheme	1).	
This	 condensation	 reaction	 demonstrated	 the	 presence	 of	 an	
acidic	 imide	 hydrogen	 in	 8a,	 which	 was	 replaced	 by	 a	
substituted	 aminomethyl	 group,	 in	 accordance	 with	 the	
findings	of	related	reports	[39‐41].		
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Reagents	and	conditions:	(a)	N2H4.H2O,	EtOH,	reflux;	(b)	Ac2O,	reflux;	(c)	Ac2CH2,	EtOH,	reflux.	
	
Scheme	2
	
	
The	mass	spectrum	of	8b	showed	a	molecular	 ion	peak	at	
m/z	 484,	 which	 is	 indicative	 of	 an	 increase	 of	 97	 from	 the	
parent	8a,	confirming	the	assigned	structure.		
Hydrazinolysis	of	the	S‐methylated	thienopyrimidinone	4a	
in	 ethanol	 provided	 the	 desired	 2‐hydrazino	 compound	 9	
(Scheme	 2).	 By	 reaction	 of	 the	 latter	 product	 with	 acetic	
anhydride	we	obtained	a	product	of	dehydrative	acetylation	for	
which	two	isomeric	structures	11	and	12	might	be	formulated.	
However,	the	structure	of	the	isolated	product	was	considered	
to	be	of	the	5‐one	type	12	rather	than	the	corresponding	4‐one	
11	 based	on	 the	established	 selective	 functionalization	of	N‐3	
for	 2‐thiouracil	 systems	 over	 derivatization	 at	 N‐1	
[20,28,33,34,42‐47].	 This	 selectivity	 can	 be	 explained	 by	 the	
enhanced	nucleophilicity	of	N‐3	as	compared	with	N‐1	position	
and	therefore	the	N‐3,	being	richer	in	electron	density,	is	more	
reactive	 towards	 electrophiles	 and	 produces	 products	 of	
exclusive	 functionalization	 at	 N‐3.	 This	 fact	 led	 to	 the	
conclusion	 that	 a	 dehydrative	 cyclization,	 involving	 the	
participation	 of	 N‐3	 and	 not	 N‐1,	 occurred	 in	 our	 studied	
reaction	 with	 the	 regioselective	 formation	 of	 the	 N‐3	 ring	
closed	 product	 12	 rather	 than	 the	 alternative	 1‐cyclized	
analogue	 11.	 The	 IR	 and	 13C	 NMR	 spectra	 provided	 further	
evidence	 for	 the	 proposed	 structure	 by	 comparison	 of	 these	
spectra	with	 those	of	 similar	annelated	pyrimidinones.	The	 IR	
spectrum	 of	 the	 isolated	 product	 showed	 an	 important	
absorption	of	the	carbonyl	group	of	the	pyrimidinone	ring	at	ν	
1698	cm‐1.	This	high	CO	stretching	frequency	is	in	favour	of	the	
pyrimidin‐5‐one	 formulation	12	 [33,43].	 It	 has	 been	 reported	
[33,48]	 that	 the	 most	 diagnostic	 signal,	 in	 the	 13C	 NMR	
spectrum	of	pyrimidin‐4‐one	systems,	is	due	to	the	carbonyl,	as	
this	 signal	 is	markedly	 affected	 by	 the	 nature	 of	 the	 adjacent	
nitrogen	(N‐3)	 (pyrrole	 type	 in	our	structure	12	and	pyridine	
type	as	in	structure	11).	Thus,	the	13C	NMR	spectrum	could	give	
unequivocal	proof	 for	 the	structure	of	 the	 isolated	product	by	
the	 observation	 of	 a	 carbonyl	 carbon	 signal	 appearing	 at	 the	
chemical	shift	of	162.7	ppm.	Such	an	upfield	shift	is	consistent	
with	pyrimidin‐5‐one	structure	12	rather	than	with	pyrimidin‐
4‐one	 11,	 for	 which	 an	 IR	 carbonyl	 absorption	 would	 be	
expected	to	appear	at	around	ν	~	1660	cm‐1	and	the	13C	NMR	
chemical	 shift	 of	 the	 carbonyl	 carbon	 would	 be	 expected	 to	
resonate	in	the	lower	field	region	(δC	~	170	ppm),	in	line	with	
prior	 observations	 of	 spectra	 of	 closely	 related	 compounds	
[33,49].	 Accordingly,	 it	 can	 be	 concluded	 that	 the	 studied	
reaction	is	completely	regioselective	and	the	linear	pyrimidin‐
5‐one	 structure	12	 of	 the	 obtained	 product	 is	 preferred	 over	
the	respective	angular	4‐one	structure	11.	It	is	believed	that	the	
formation	of	compound	12	proceeds	through	the	intermediacy	
of	 the	 acetylhydrazino	 10	 followed	 by	 intramolecular	
cyclodehydration	 under	 the	 applied	 reaction	 conditions	
(Scheme	2).	
Nevertheless,	 a	 proof	 for	 the	 proposed	 structure	 12	was	
accomplished	chemically	by	using	an	independent	route	for	the	
synthesis	 of	 compound	 12	 involving	 initial	 acetylation	 of	 4a	
with	acetic	anhydride	and	subsequent	treatment	of	the	formed	
N‐acetyl	 derivative	 13	 with	 hydrazine	 hydrate,	 yielding	 a	
product	 (55%)	 that	 proved	 to	 be	 identical	 to	 the	 previous	
product	12	as	confirmed	by	TLC	analysis,	melting	point,	IR	data	
and	 undepressed	 mixed	 melting	 point	 with	 the	 previously	
isolated	material.	
It	is	remarkable	to	report	here	that	an	unexpected	reaction	
took	 place	 on	 reacting	9	with	 acetylacetone	 in	 an	 attempt	 to	
obtain	 the	 dimethylpyrazolyl	 derivative	 15.	 To	 our	 surprise,	
this	reaction	did	not	give	the	expected	product	15	and	instead	
the	 methyltriazole	 derivative	 12	 was	 again	 obtained,	 the	
structure	 of	 which	 was	 unambiguously	 confirmed	 by	
comparison	of	TLC	analysis,	m.p.,	mixed	m.p.	and	IR	data	with	
those	of	the	previously	isolated	sample	12.		
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Reagents	and	conditions:	(a)	PhCOCH2Br,	DMF,	Et3N,	reflux;	(b)	CH2(CN)2,	EtOH,	pip,	reflux;	
(c)	CH2(CN)2,	NaOEt,	EtOH,	reflux;	(d)	NaOEt,	EtOH,	reflux.	
	
Scheme	3
	
	
This	 result	 can	 be	 explained	 by	 assuming	 the	 reaction	
occurs	 initially	 with	 formation	 of	 a	 α‐hydroxyhydrazine	 14.	
Subsequent	 loss	 of	 water	 and	 acetone,	 respectively,	 leads	
eventually	 to	 the	 final	 methyltriazole	 derivative	 12.	 This	
hypothesis	is	consistent	with	similar	observations	[50‐52].	
This	 approach	 was	 also	 suitable	 for	 the	 synthesis	 of	 a	
condensed	 pyrrole	 system,	 where	 reaction	 of																																		
2‐aminothiophene	 1	 with	 phenacyl	 bromide	 afforded	 the	
respective	 phenacylamine	 derivative	 16	 via	 the	 nucleophilic	
displacement	 of	 the	 bromine	 by	 the	 heterocyclic	 amine.	
Condensation	 of	 16	 with	 malononitrile	 in	 ethanol	 in	 the	
presence	of	piperidine	produced	the	enaminonitrile	derivative	
18	 through	 the	 intermediate	 formation	 of	 17	 followed	 by	
subsequent	nucleophilic	cyclization	under	the	applied	reaction	
conditions.	Heteroannelation	of	18	in	boiling	ethanolic	sodium	
ethoxide	 solution	 occurred	with	 the	 formation	 of	 the	 tricyclic	
pyrrole	derivative	19,	via	loss	of	ethanol	(Scheme	3).	It	is	worth	
mentioning	 that	compound	19	could	be	also	obtained	directly	
in	 a	 reaction	 of	 phenacylamine	 derivative	 16	 with	
malononitrile	 in	 boiling	 ethanolic	 sodium	 ethoxide	 solution.	
Compound	 19	 prepared	 by	 the	 latter	 route	 was	 found	 to	 be	
identical	to	that	obtained	by	the	former	method.	Elucidation	of	
structure	for	the	latter	product	was	established	on	the	basis	of	
elemental	 and	 spectroscopic	 analyses	 (see	 Experimental	
section).	
	
3.2.	Antimicrobial	Evaluation	
	
The	 biological	 evaluation	 of	 antibacterial	 and	 antifungal	
effects	 are	 summarized	 in	Tables	1	 and	2.	As	 shown	by	 these	
results,	 the	 new	 bridgehead	 nitrogen	 heterocycles	 under	
investigation	 displayed	 variable	 in	 vitro	 antibacterial	 and	
antifungal	 actions.	 In	 general,	 the	 chemical	 structure,	
comprising	the	nature	of	the	heterocyclic	system	as	well	as	the	
substituted	 function	 present	 in	 the	 heterocyclic	 ring,	 has	 a	
pronounced	effect	on	antimicrobial	activity.	In	particular,	it	was	
found	that	the	attachment	of	a	N‐(piperidinylmethyl)imidazole	
pharmacophore	 to	 the	 thienopyrimidinone	 core	 favoured	
antibacterial	 activity	 especially	 against	 the	 Gram‐negative	
strain,	as	observed	for	compound	8b,	whereas	the	annelation	of	
a	 3‐phenylthiazole	 moiety	 to	 the	 same	 core	 produced	 an	
inhibitory	effect	against	Gram‐positive	bacteria	superior	to	the	
reference	 drug	 chloramphenicol	 as	 observed	 for	 compound	5	
(Table	 1).	 As	 for	 antifungal	 action,	 compound	 12,	 which	
incorporated	a	3‐methyltriazole	fragment,	exhibited	the	highest	
effect	on	yeast	(C.	albicans)	with	potency	1.13,	whilst	the	most	
prominent	and	consistent	antifungal	activity	was	obtained	with	
3‐phenylthiazole	 derivative	 5,	 which	 produced	 inhibitory	
effects	 similar	 or	 superior	 to	 the	 reference	 drug	 fluconazole	
with	 potency	 1.0	 (Table	 2).	 On	 the	 contrary,	 there	 was	 no	
essential	in	vitro	antimicrobial	profile	of	compound	8a	with	an	
N‐1‐unsubstituted	triazole	moiety.	
Based on	 the	biological	evaluation,	 compounds	8b	and	12	
were	selected	for	further	assessment.	The	minimum	inhibitory	
concentration	 (MIC)	 of	 N‐(piperidinylmethyl)imidazole	
derivative	8b	against	P.	aeruginosa	was	15.5	µg/mL,	which	 is	
less	 than	 that	 of	 chloramphenicol	 as	 a	 reference	 antibacterial	
drug	as	depicted	 in	Table	3.	Also,	 the	MIC	of	3‐methyltriazole	
derivative	12	against	C.	albicans	was	13.5	µg/mL,	which	is	less	
than	 that	 of	 fluconazole	 as	 a	 reference	 antifungal	 drug	 (Table	
3).	 From	 the	 structure‐activity	 relationship	 (SAR),	 we	 can	
conclude	 that	 the	 N‐piperidinylmethyl	 pharmacophore	 is	
important	 for	 antibacterial	 activity,	 especially	 against	 P.	
aeruginosa	 as	 observed	 for	 compound	 8b.	 In	 addition,	
heteroannelation	 of	 a	 3‐methyltriazole	 moiety	 to	 the	
thienopyrimidinone	scaffold	can	improve	anti‐Candida	activity	
as	 observed	 for	 compound	12,	 which	 can	 be	 considered	 as	 a	
lead	compound	in	this	field.	Further	studies	are	in	progress	on	
both	compounds	to	increase	their	efficacy	and	understand	their	
QSAR.	
	
4.	Conclusion	
	
In	 conclusion,	 we	 have	 demonstrated	 that	 the	
heterocyclization	 of	 2‐(alkylthio)pyrimidine‐type	 building	
blocks	4	and	 its	parent	ortho‐aminoester	1	provided	easy	and	
versatile	 access	 to	 a	 variety	 of	 bridgehead	 nitrogen	
heterocycles,	 which	 were	 of	 significant	 interest	 for	 biological	
investigations.	 The	 biological	 potential	 of	 all	 new	 N‐hetero‐
cyclic	 derivatives	 was	 further	 investigated	 by	 screening	 their	
antimicrobial	activity	against	two	pathogenic	bacteria	and	two	
pathogenic	 fungi.	 Biological	 study	 of	 the	 compounds	 under	
investigation	 indicated	 that	 the	 highest	 anti‐Candida	 activity	
was	observed	for	compound	12	with	a	methyl	group	attached	
to	the	triazole	ring	at	the	3‐position.	Its	MIC	value	(13.5	µg/mL)	
towards	C.	albicans	 very	significant.	Compound	8b	showed	an	
appreciable	 broad	 spectrum	 of	 action	 against	 both	 Gram‐
positive	 and	 Gram‐negative	 bacteria.	 Its	 MIC	 value	 (15.5	
µg/mL)	towards	P.	aeruginosa	is	very	interesting.	In	light	of	the	
results	presented	in	this	work	and	taking	into	account	that	this	
preliminary	 study	 does	 not	 produce	 conclusive	 evidence	
regarding	 structure‐antimicrobial	 relationships,	 we	 have	
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focused	 our	 attention	 on	 the	 most	 promising	 compounds	 8b	
and	12	as	an	interesting	starting	point	for	the	development	of	a	
new	 class	 of	 antimicrobial	 agents.	 Further	 structural	
modifications	 might	 lead	 to	 the	 discovery	 of	 more	 potent	
antimicrobial	 agents	 and	 this	work	 is	 in	 progress.	We	believe	
that	research	in	this	direction	should	be	encouraged	in	order	to	
broaden	the	applicability	of	these	new	heterocyclic	frameworks	
to	serve	as	leads	for	designing	novel	chemotherapeutic	agents.	
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